Pierre L.
- Country
- France
- Department
- Onco-Hématologie
Research Overview
- Phase 3 Study of Isatuximab, Lenalidomide, and Dexamethasone ± Bortezomib in Non-Frail, Transplant-Ineligible Elderly Patients with Newly Diagnosed Multiple Myeloma
- Minimal Residual Disease-Adapted Strategy in Multiple Myeloma: Evaluation of Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone in Transplant-Eligible Patients
- Comparison of Apixaban, Rivaroxaban, and Acetylsalicylic Acid for Thromboembolic Prevention in JAK2V617F-Positive Myeloproliferative Neoplasms
Data & Insights
Has run more than one trial at 78 of 113 partner sites.
Specializations
Multiple Myeloma Management
This investigator specializes in developing therapeutic strategies for multiple myeloma, with particular emphasis on minimal residual disease (MRD) assessment and adaptation of treatment protocols.
- Newly Diagnosed Multiple Myeloma
- Transplant-Eligible and Ineligible Patients
- MRD-Based Treatment Strategies
The research explores innovative combinations including isatuximab, lenalidomide, and elranatamab for various patient populations.
Elderly Patient Care
Focused on developing specialized treatments for elderly multiple myeloma patients, particularly those who are transplant-ineligible and non-frail.
- Age-Adapted Therapy Protocols
- Frailty-Based Treatment Approaches
- Quality of Life Optimization
Special attention is given to subcutaneous treatment delivery methods and reduced-intensity therapeutic regimens.
Hematological Disorders
The investigator studies myeloproliferative neoplasms and their complications, with particular focus on preventing thromboembolic events.
- JAK2V617F-Positive Neoplasms
- Thrombosis Prevention
- Chronic Myeloid Conditions
Research encompasses various conditions including polycythemia vera, essential thrombocythemia, and myelofibrosis.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.